We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Roche Holding, Exxon Mobil, Honeywell, Equinix and Aon
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 11, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche Holding AG (RHHBY - Free Report) , Exxon Mobil Corp. (XOM - Free Report) , Honeywell International Inc. (HON - Free Report) , Equinix, Inc. (EQIX - Free Report) and Aon plc (AON - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Roche, Exxon Mobil and Honeywell
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche Holding, Exxon Mobil, and Honeywell. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Roche have performed in line with the Zacks Large Cap Pharmaceuticals industry in the year-to-date period (+12.6% vs. +12.3%). The Zacks analyst believes that a significant presence in the oncology market, strong demand for its breast cancer drugs and the expansion of portfolio into immunology are the major positives for Roche.
The base diagnostics business has maintained its momentum on the back of strong demand for COVID-19 tests. A steady growth in Ocrevus, Evrysdi, Tecentriq, and Hemlibra continues to boost revenues. Stiff competition from biosimilars for some of Roche’s key drugs such as Avastin, MabThera/Rituxan and Herceptin are likely to impact sales in the near term.
Exxon Mobil shares have gained +92.1% over the past year against the Zacks Integrated International Oil industry’s gain of +77.1%. The Zacks analyst believes that major discoveries in the Stabroek Block have enhanced prospects for ExxonMobil's upstream businesses. The company recently raised the estimate for discovered recoverable resources from the Stabroek Block to approximately 10 billion oil-equivalent barrels.
Its optimal integrated capital structure as well as management's track record of CAPEX discipline across the commodity price cycle make it a relatively lower-risk energy sector play. Above-average capital spending program, weakness in the downstream business, and lower estimated profits from its chemical business are some of the major headwinds though.
Shares of Honeywell have lost -3.6% over the past six months against the Zacks Diversified Operations industry’s gain of +5.8%, however, things seem to be improving for the company. The Zacks analyst believes that Honeywell is set to benefit from strength in warehouse and workflow solutions businesses in the quarters ahead.
Cost control as well as operational excellence initiatives, acquisitions and a strong cash flow are some of the other tailwinds. Weakness in defense and space businesses, high-debt levels and high costs and operating expenses are likely to weigh on its revenues though.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Roche Holding, Exxon Mobil, Honeywell, Equinix and Aon
For Immediate Release
Chicago, IL – October 11, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche Holding AG (RHHBY - Free Report) , Exxon Mobil Corp. (XOM - Free Report) , Honeywell International Inc. (HON - Free Report) , Equinix, Inc. (EQIX - Free Report) and Aon plc (AON - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Research Reports for Roche, Exxon Mobil and Honeywell
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche Holding, Exxon Mobil, and Honeywell. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Roche have performed in line with the Zacks Large Cap Pharmaceuticals industry in the year-to-date period (+12.6% vs. +12.3%). The Zacks analyst believes that a significant presence in the oncology market, strong demand for its breast cancer drugs and the expansion of portfolio into immunology are the major positives for Roche.
The base diagnostics business has maintained its momentum on the back of strong demand for COVID-19 tests. A steady growth in Ocrevus, Evrysdi, Tecentriq, and Hemlibra continues to boost revenues. Stiff competition from biosimilars for some of Roche’s key drugs such as Avastin, MabThera/Rituxan and Herceptin are likely to impact sales in the near term.
(You can read the full research report on Roche here >>>)
Exxon Mobil shares have gained +92.1% over the past year against the Zacks Integrated International Oil industry’s gain of +77.1%. The Zacks analyst believes that major discoveries in the Stabroek Block have enhanced prospects for ExxonMobil's upstream businesses. The company recently raised the estimate for discovered recoverable resources from the Stabroek Block to approximately 10 billion oil-equivalent barrels.
Its optimal integrated capital structure as well as management's track record of CAPEX discipline across the commodity price cycle make it a relatively lower-risk energy sector play. Above-average capital spending program, weakness in the downstream business, and lower estimated profits from its chemical business are some of the major headwinds though.
(You can read the full research report on Exxon Mobil here >>>)
Shares of Honeywell have lost -3.6% over the past six months against the Zacks Diversified Operations industry’s gain of +5.8%, however, things seem to be improving for the company. The Zacks analyst believes that Honeywell is set to benefit from strength in warehouse and workflow solutions businesses in the quarters ahead.
Cost control as well as operational excellence initiatives, acquisitions and a strong cash flow are some of the other tailwinds. Weakness in defense and space businesses, high-debt levels and high costs and operating expenses are likely to weigh on its revenues though.
(You can read the full research report on Honeywell here >>>)
Other noteworthy reports we are featuring today include Equinix and Aon.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.